ATE386508T1 - Feste orale dosierungsform enthaltend einen resorptionsverstärker - Google Patents

Feste orale dosierungsform enthaltend einen resorptionsverstärker

Info

Publication number
ATE386508T1
ATE386508T1 AT00905186T AT00905186T ATE386508T1 AT E386508 T1 ATE386508 T1 AT E386508T1 AT 00905186 T AT00905186 T AT 00905186T AT 00905186 T AT00905186 T AT 00905186T AT E386508 T1 ATE386508 T1 AT E386508T1
Authority
AT
Austria
Prior art keywords
dosage form
oral dosage
solid oral
enhancer
form containing
Prior art date
Application number
AT00905186T
Other languages
English (en)
Inventor
Kenneth Cumming
Zebunnissa Ramtoola
Original Assignee
Merrion Res I Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrion Res I Ltd filed Critical Merrion Res I Ltd
Application granted granted Critical
Publication of ATE386508T1 publication Critical patent/ATE386508T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
AT00905186T 1999-02-22 2000-02-22 Feste orale dosierungsform enthaltend einen resorptionsverstärker ATE386508T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12104899P 1999-02-22 1999-02-22

Publications (1)

Publication Number Publication Date
ATE386508T1 true ATE386508T1 (de) 2008-03-15

Family

ID=22394170

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00905186T ATE386508T1 (de) 1999-02-22 2000-02-22 Feste orale dosierungsform enthaltend einen resorptionsverstärker

Country Status (8)

Country Link
EP (1) EP1154761B1 (de)
JP (2) JP2002537321A (de)
AT (1) ATE386508T1 (de)
AU (1) AU2681300A (de)
CA (1) CA2363123C (de)
DE (1) DE60038097T2 (de)
ES (1) ES2301477T3 (de)
WO (1) WO2000050012A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1719800A (en) 1998-11-13 2000-06-05 Elan Pharma International Limited Drug delivery systems and methods
US7084279B1 (en) 1999-02-11 2006-08-01 Emisphere Technologies Inc. Oxadiazole compounds and compositions for delivering active agents
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
JP2007016034A (ja) * 2000-12-26 2007-01-25 Kirin Brewery Co Ltd 吸収促進剤
CA2438707A1 (en) * 2001-02-16 2002-08-22 Akihiro Matsuura Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
JP4489356B2 (ja) * 2001-05-11 2010-06-23 メリオン リサーチ スリー リミテッド 浸透促進剤
KR20070044805A (ko) 2004-04-15 2007-04-30 키아스마, 인코포레이티드 생물학적 장벽 투과를 촉진시킬 수 있는 조성물
UA103758C2 (ru) * 2004-07-19 2013-11-25 Биокон Лимитед Конъюгаты олигомеров инсулина, их композиции и применение
AU2014200247B2 (en) * 2004-07-19 2015-05-14 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
EP1781257B1 (de) * 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmazeutische formulierungen mit mikropartikeln oder nanopartikeln eines zufuhrmittels
JP4759289B2 (ja) * 2005-03-02 2011-08-31 国立大学法人北海道大学 カルシウム吸収促進組成物およびその利用
ES2426445T3 (es) * 2006-04-07 2013-10-23 Merrion Research Iii Limited Forma de dosificación oral sólida que contiene un potenciador
EP2040731A4 (de) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd Feste orale dosierform mit einem verstärkungsmittel
AR062721A1 (es) * 2006-09-12 2008-11-26 Glaxo Group Ltd Composicion farmaceutica de liberacion modificada para administracion oral que comprende una pluralidad de mini- comprimidos con un inhibidor del factor xa, su uso para prpeparar un medicamento y proceso para prepararla
BRPI0818004B8 (pt) * 2007-10-16 2021-05-25 Biocon Ltd composição farmacêutica sólida administrável por via oral e o processo da mesma.
AU2008324787B2 (en) * 2007-11-05 2013-10-10 Ala Wai Pharma, Inc. Formulations for enhanced bioavailability of orally administered polar agents
TW200950801A (en) * 2008-05-07 2009-12-16 Merrion Res Iii Ltd Compositions of peptides and processes of preparation thereof
NZ591810A (en) 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
GB0904942D0 (en) * 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
PT2459176T (pt) 2009-07-31 2017-12-11 Gruenenthal Gmbh Método de cristalização e biodisponibilidade
CA2784120A1 (en) 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
AU2011341637A1 (en) * 2010-12-15 2013-06-20 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
KR20140026354A (ko) * 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 경구 투여용 철의 제약 조성물
MX355361B (es) 2011-04-12 2018-04-17 Novo Nordisk As Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
RU2641198C3 (ru) 2012-03-22 2021-12-10 Ново Нордиск А/С Композиции glp-1 пептидов и их получение
SI2827845T1 (sl) 2012-03-22 2019-04-30 Novo Nordisk A/S Sestavki, ki obsegajo dostavno sredstvo in njihova priprava
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
EP3250191B1 (de) 2015-01-29 2024-01-17 Novo Nordisk A/S Tabletten mit glp-1-agonisten und magensaftresistentem überzug
CA2975599A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
LT3280447T (lt) * 2015-04-08 2019-05-27 Torrent Pharmaceuticals Limited Farmacinės kompozicijos
GB201515387D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
CN108699126B (zh) 2016-03-03 2022-12-06 诺和诺德股份有限公司 Glp-1衍生物及其用途
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
WO2019016300A1 (en) 2017-07-19 2019-01-24 Novo Nordisk A/S EGF ANALOGUES (A), PREPARATION, FORMULATIONS AND USES THEREOF
IL275778B2 (en) 2018-02-02 2023-12-01 Novo Nordisk As Solid compounds that make up glp-1 agonist n-8-2-hydroxybenzoyl salt
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
WO2024143501A1 (ja) * 2022-12-28 2024-07-04 中外製薬株式会社 分散対象物質を含む固体分散体、それを含む医薬組成物及びそれらの製造方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB953626A (en) * 1961-04-25 1964-03-25 Meito Sangyo Kk Enteric-coated tablets of dextran sulphate ester and method of preparation thereof
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS5973600A (ja) * 1982-10-19 1984-04-25 Okayasu Shoten:Kk 排卵誘発剤
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
ZA898331B (en) * 1988-11-22 1990-07-25 Hoffmann La Roche Pharmaceutical compositions
JPH03275633A (ja) * 1990-03-23 1991-12-06 Teikoku Seiyaku Co Ltd 生理活性ポリペプチドの吸収促進剤
JPH04149126A (ja) 1990-10-09 1992-05-22 Mitsubishi Kasei Corp 経粘膜投与用医薬組成物
IT1245761B (it) * 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
CA2070061C (en) * 1991-06-07 2004-02-10 Shigeyuki Takama Physiologically active polypeptide-containing pharmaceutical composition
HU227530B1 (en) * 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
SE501389C2 (sv) * 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
RU2068689C1 (ru) * 1992-09-24 1996-11-10 Товарищество с ограниченной ответственностью "Лекрон" Способ получения таблеток парацетамола
DK0667148T3 (da) * 1992-11-06 2002-07-22 Hisamitsu Pharmaceutical Co Peroralt farmaceutisk præparat, der udløses i den nedre del af mavetarmkanalen
JPH06192107A (ja) 1992-12-25 1994-07-12 Sanwa Kagaku Kenkyusho Co Ltd グリチルリチン経口剤
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
GB9614235D0 (en) * 1996-07-06 1996-09-04 Danbiosyst Uk Composition for enhanced uptake of polar drugs from mucosal surfaces

Also Published As

Publication number Publication date
JP5412491B2 (ja) 2014-02-12
EP1154761A1 (de) 2001-11-21
CA2363123A1 (en) 2000-08-31
WO2000050012A1 (en) 2000-08-31
JP2002537321A (ja) 2002-11-05
AU2681300A (en) 2000-09-14
DE60038097T2 (de) 2009-02-12
EP1154761B1 (de) 2008-02-20
DE60038097D1 (de) 2008-04-03
JP2012067115A (ja) 2012-04-05
ES2301477T3 (es) 2008-07-01
CA2363123C (en) 2011-09-06

Similar Documents

Publication Publication Date Title
ATE386508T1 (de) Feste orale dosierungsform enthaltend einen resorptionsverstärker
MY151458A (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
HUP0401963A3 (en) Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
BRPI0417043A (pt) composição farmacêutica, forma de dosagem sólida, método de manufatura de forma de dosagem sólida, e, uso da composição
YU23599A (sh) Stabilizovani antihistaminski sirup
DK1163234T3 (da) Farmaceutiske formuleringer med forbedret vandoplöselighed
TR199900674T2 (xx) Kinazolin t�revleri ve bunlar� i�eren farmas�tik bile�imler.
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
CA2356380A1 (en) Immunosuppressive effects of pteridine derivatives
WO2000045800A3 (en) Immunosurpressive effects of pteridine derivatives
TR199802060T2 (xx) Aminoisokinolinler ve aminopiridin t�revlerinin iltihap �nleyiciler olarak kullan�m�.
HUP0203716A3 (en) Substituted n-benzyl-indol-3-yl glyoxylic acid derivatives having an anti-tumoral effect and pharmaceutical compositions containing them
CY1112057T1 (el) Θεραπευτικος παραγων για διαταραχη επαρκειας τροφης στο στομαχι
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
AR032614A1 (es) Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina
IL131216A0 (en) Drugs inhibiting progress of pterygium and postoperative recurrence of the same
WO2002009717A1 (fr) Remedes contre la dyserection contenant des derives de prostaglandine comme principe actif
ATE291421T1 (de) Pharmazeutische, ramipril enthaltende brauseformulierung
CA2362833A1 (en) Phenylalaninol derivatives
ATE236885T1 (de) Hydrazono-benzazulen-derivate, pharmazeutische zusammensetzungen und zwischenprodukte
IT1306147B1 (it) Derivati di principi attivi ad attivita' terapeutica e/o nutrizionalee composizioni atte alla somministrazione orale contenenti tali
FI964918A (fi) Lääkeainesuoloja
SE9902742D0 (sv) New pharmaceutical formultion
IL161768A0 (en) Carboxylic acid derivative compounds and drugs containing the same as the active ingredient
AU2002363776A1 (en) Carboxylic acid derivative compounds and drugs containing the same as the active ingredient

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties